Variant report
Variant | nsv610014 |
---|---|
Chromosome Location | chr8:6791715-6794400 |
allele | n/a |
Outlinks | Ensembl   UCSC |
- TF binding region (count:0)
- CpG islands (count:0)
- Chromatin interactive region (count:1)
- LncRNA region (count:0)
- Mature miRNA region (count: 0)
- miRNA target sites (count:0)
No data |
No data |
(count:1 , 50 per page) page:
1
No. | Distal block | Cell Line | Cell type | Cell Stage |
---|---|---|---|---|
1 | chr8:6775337..6778035-chr8:6790742..6792474,2 | K562 | blood: |
No data |
No data |
No data |
No data |
No. | Variant name | Chromosome position | Chromatin state | Related regulatory elements | Target genes | Extended variants | Associated traits |
---|---|---|---|---|---|---|---|
1 | rs2738106 | chr8:6791715-6791716 | Enhancers Weak transcription Flanking Active TSS | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
2 | rs188212391 | chr8:6791720-6791721 | Enhancers Weak transcription Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
3 | rs73195968 | chr8:6791747-6791748 | Enhancers Weak transcription Flanking Active TSS | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
4 | rs573259139 | chr8:6791760-6791761 | Enhancers Weak transcription Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
5 | rs180735423 | chr8:6791778-6791779 | Enhancers Weak transcription Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
6 | rs76545915 | chr8:6791795-6791796 | Enhancers Weak transcription Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
7 | rs185995383 | chr8:6791805-6791806 | Bivalent Enhancer Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
8 | rs13261705 | chr8:6791840-6791841 | Bivalent Enhancer Enhancers Flanking Active TSS | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
9 | rs118073035 | chr8:6791845-6791846 | Bivalent Enhancer Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
10 | rs573541048 | chr8:6791851-6791852 | Bivalent Enhancer Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
11 | rs142774534 | chr8:6791857-6791858 | Bivalent Enhancer Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
12 | rs559248855 | chr8:6791876-6791877 | Bivalent Enhancer Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
13 | rs528047761 | chr8:6791891-6791892 | Bivalent Enhancer Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
14 | rs147352135 | chr8:6791898-6791899 | Bivalent Enhancer Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
15 | rs564788973 | chr8:6791911-6791912 | Bivalent Enhancer Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
16 | rs548540281 | chr8:6791924-6791925 | Bivalent Enhancer Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
17 | rs2738105 | chr8:6791940-6791941 | Bivalent Enhancer Enhancers Flanking Active TSS | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
18 | rs189726321 | chr8:6791949-6791950 | Bivalent Enhancer Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
19 | rs550453033 | chr8:6791960-6791961 | Bivalent Enhancer Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
20 | rs567842328 | chr8:6791971-6791972 | Bivalent Enhancer Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
21 | rs530352139 | chr8:6791974-6791975 | Bivalent Enhancer Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
22 | rs547293584 | chr8:6791983-6791984 | Bivalent Enhancer Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
23 | rs567194192 | chr8:6791996-6791997 | Bivalent Enhancer Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
24 | rs144914575 | chr8:6792000-6792001 | Bivalent Enhancer Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
25 | rs181339236 | chr8:6792008-6792009 | Enhancers Flanking Active TSS Bivalent Enhancer | n/a | n/a | Overlapped CNVs | n/a |
26 | rs144821340 | chr8:6792014-6792015 | Enhancers Flanking Active TSS Bivalent Enhancer | n/a | n/a | Overlapped CNVs | n/a |
27 | rs148591643 | chr8:6792018-6792019 | Enhancers Flanking Active TSS Bivalent Enhancer | n/a | n/a | Overlapped CNVs | n/a |
28 | rs142899391 | chr8:6792020-6792021 | Enhancers Flanking Active TSS Bivalent Enhancer | n/a | n/a | Overlapped CNVs | n/a |
29 | rs2702865 | chr8:6792058-6792059 | Enhancers Flanking Active TSS Bivalent Enhancer | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
30 | rs542432724 | chr8:6792084-6792085 | Enhancers Flanking Active TSS Bivalent Enhancer | n/a | n/a | Overlapped CNVs | n/a |
31 | rs552812047 | chr8:6792091-6792092 | Enhancers Flanking Active TSS Bivalent Enhancer | n/a | n/a | Overlapped CNVs | n/a |
32 | rs558557166 | chr8:6792101-6792102 | Enhancers Flanking Active TSS Bivalent Enhancer | n/a | n/a | Overlapped CNVs | n/a |
33 | rs190483884 | chr8:6792103-6792104 | Enhancers Flanking Active TSS Bivalent Enhancer | n/a | n/a | Overlapped CNVs | n/a |
34 | rs183448746 | chr8:6792111-6792112 | Enhancers Flanking Active TSS Bivalent Enhancer | n/a | n/a | Overlapped CNVs | n/a |
35 | rs558022717 | chr8:6792138-6792139 | Enhancers Flanking Active TSS Bivalent Enhancer | n/a | n/a | Overlapped CNVs | n/a |
36 | rs564896971 | chr8:6792171-6792172 | Enhancers Flanking Active TSS Bivalent Enhancer | n/a | n/a | Overlapped CNVs | n/a |
37 | rs530467016 | chr8:6792215-6792216 | Enhancers Bivalent Enhancer Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
38 | rs577805008 | chr8:6792226-6792227 | Enhancers Bivalent Enhancer Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
39 | rs544282141 | chr8:6792239-6792240 | Enhancers Bivalent Enhancer Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
40 | rs2738104 | chr8:6792257-6792258 | Enhancers Bivalent Enhancer Flanking Active TSS | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
41 | rs151092739 | chr8:6792277-6792278 | Enhancers Bivalent Enhancer Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
42 | rs186354570 | chr8:6792282-6792283 | Enhancers Bivalent Enhancer Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
43 | rs567121579 | chr8:6792308-6792309 | Enhancers Bivalent Enhancer Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
44 | rs541762114 | chr8:6792311-6792312 | Enhancers Bivalent Enhancer Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
45 | rs532851601 | chr8:6792322-6792323 | Enhancers Bivalent Enhancer Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
46 | rs141296099 | chr8:6792346-6792347 | Enhancers Bivalent Enhancer Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
47 | rs569220176 | chr8:6792359-6792360 | Enhancers Bivalent Enhancer Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
48 | rs561526174 | chr8:6792385-6792386 | Enhancers Bivalent Enhancer Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
49 | rs537877563 | chr8:6792393-6792394 | Enhancers Bivalent Enhancer Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
50 | rs13263461 | chr8:6792401-6792402 | Enhancers Bivalent Enhancer Flanking Active TSS | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
Disease | PMID | Source |
---|---|---|
Ovarian clear cell carcinoma | 21343371 | CNVD |
abnormal development | 18461090 | CNVD |
Crohn''s disease | 19220326 | CNVD |
Psoriasis | 19220326 | CNVD |
Prostate cancer | 21965145 | CNVD |
Prostate cancer | 18515986 | CNVD |
Chronic obstructive pulmonary disease | 20378733 | CNVD |
Autism | 18414403 | CNVD |
Cancer | 21183584 | CNVD |
Non-syndromic sensorineural hearing loss | 15273396 | CNVD |
Breast cancer | 17603634 | CNVD |
Myeloproliferative neoplasm | 20015882 | CNVD |
Ovarian cancer | 20844748 | CNVD |
Cervical cancer | 17311676 | CNVD |
High-grade prostatic intraepithelial neoplasia | 16573809 | CNVD |
Non-syndromic sensorineural hearing loss | 20606397 | CNVD |
Schizophrenia | 20877625 | CNVD |
Disorders of sex development | 21048976 | CNVD |
Colorectal cancer | 16272173 | CNVD |
Basal cell lymphoma | 17170743 | CNVD |
Follicular lymphoma | 17170743 | CNVD |
Breast cancer | 17001317 | CNVD |
Thyroid cancer | 19087340 | CNVD |
Multiple myeloma | 16616336 | CNVD |
Hepatocellular carcinoma | 22174799 | CNVD |
Heart disease | 21282601 | CNVD |
Prostate cancer | 16573809 | CNVD |
T-cell lymphomas | 19863542 | CNVD |
Ovarian cancer | 22174824 | CNVD |
Colorectal cancer | 21297112 | CNVD |
Hodgkin''s lymphoma | 18641027 | CNVD |
Salivary gland tumor | 18059337 | CNVD |
Breast cancer | 17133270 | CNVD |
Melanoma | 18172304 | CNVD |
Medulloblastoma | 21979893 | CNVD |
Chronic lymphocytic leukemia | 18922857 | CNVD |
Breast cancer | 17393978 | CNVD |
Chronic lymphocytic leukemia | 21546498 | CNVD |
Cancer | 21637783 | CNVD |
Breast cancer | 20837533 | CNVD |
Squamous cell cancer | 21044232 | CNVD |
Acute lymphoblastic leukemia | 20435627 | CNVD |
Cancer | 22429812 | CNVD |
Non-small cell lung cancer | 21044232 | CNVD |
Non-syndromic sensorineural hearing loss | 18471307 | CNVD |
T-cell prolymphocytic leukemia | 19278963 | CNVD |
Colorectal cancer | 20709793 | CNVD |
Ewing''s sarcoma | 21437220 | CNVD |
Glioblastoma multiforme | 21080181 | CNVD |
Endometrial cancer | 22040021 | CNVD |
Basal cell lymphoma | 21115979 | CNVD |
Breast cancer | 21264507 | CNVD |
Carcinoma ex pleomorphic adenoma | 18828159 | CNVD |
Esophageal squamous carcinoma | 21637470 | CNVD |
Glioblastoma multiforme | 19960244 | CNVD |
Oral cancer | 21386901 | CNVD |
Prostate cancer | 21088497 | CNVD |
Breast cancer | 20940404 | CNVD |
Colorectal cancer | 19359472 | CNVD |
Embryonal rhabdomyosarcoma | 16790082 | CNVD |
Gastric cancer | 17167181 | CNVD |
Prostate cancer | 16705090 | CNVD |
8p-syndrome | 17576883 | CNVD |
Human rectal carcinomas | 16397240 | CNVD |
Medulloblastoma | 16968546 | CNVD |
Lung adenocarcinoma | 19525976 | CNVD |
Lung cancer | 19525976 | CNVD |
Prostate cancer | 17245344 | CNVD |
Gastrointestinal stromal cancer | 16982739 | CNVD |
Cancer | 16751803 | CNVD |
Wilms tumour | 21544195 | CNVD |
Gastric cancer | 17908304 | CNVD |
Autism | 19415332 | CNVD |
Malaria | 21533027 | CNVD |
Non-syndromic sensorineural hearing loss | 22037309 | CNVD |
Esophageal cancer | 21851588 | CNVD |
Acute promyelocytic leukemia | 19109227 | CNVD |
Breast cancer | 21245420 | CNVD |
Acute lymphoblastic leukemia | 21248843 | CNVD |
Breast cancer | 21785460 | CNVD |
Thoracic aortic aneurysm | 21092924 | CNVD |
Acute myeloid leukemia | 20729466 | CNVD |
Breast cancer | 21509527 | CNVD |
T-cell prolymphocytic leukemia | 17713554 | CNVD |
Acute lymphoblastic leukemia | 22237106 | CNVD |
Epilepsy | 22083797 | CNVD |
Acute myeloid leukemia | 21251322 | CNVD |
low-grade B-cell lymphoma tumor | 18367492 | CNVD |
Prostate cancer | 18632612 | CNVD |
Breast cancer | 21858162 | CNVD |
lymphocytic leukemia | 21291569 | CNVD |
Liver carcinoma | 19366792 | CNVD |
Hodgkin''s lymphoma | 17606441 | CNVD |
Congenital diaphragmatic hernia | 21064195 | CNVD |
Autism | 22495311 | CNVD |
Myelofibrosis | 22110671 | CNVD |
Intellectual disability | 22045946 | CNVD |
Malignant fibrous histiocytomas | 21085701 | CNVD |
Breast cancer | 16608533 | CNVD |
Seminomas | 18059402 | CNVD |
Lung cancer | 18438408 | CNVD |
small cell lung cancer | 20016488 | CNVD |
Colorectal cancer | 16774939 | CNVD |
Breast cancer | 21364760 | CNVD |
Lung squamous cell carcinoma | 22363434 | CNVD |
Cancer | 20164919 | CNVD |
Medulloblastoma | 16783165 | CNVD |
Gastric cancer | 18160780 | CNVD |
Breast cancer | 21990379 | CNVD |
Psoriasis | 20403174 | CNVD |
Psoriasis | 20663923 | CNVD |
Crohn''s disease | 16909382 | CNVD |
Cancer | 21129771 | CNVD |
Congenital diaphragmatic hernia | 21085971 | CNVD |
Crohn''s disease | 20877625 | CNVD |
Inflammatory disorder | 20877625 | CNVD |
Cardiac defect | 21933911 | CNVD |
Psoriasis | 18059266 | CNVD |
Barrett''s adenocarcinoma | 18663352 | CNVD |
Psoriasis | 20877625 | CNVD |
Mental retardation | 17847001 | CNVD |
Prostate cancer | 17217626 | CNVD |
Schizophrenia | 21399695 | CNVD |
Colorectal cancer | 21128281 | CNVD |
Colorectal cancer | 19455253 | CNVD |
Psoriasis | 18848619 | CNVD |
Squamous cell cancer | 19047905 | CNVD |
Colorectal cancer | 17229543 | CNVD |
Gastrointestinal stromal cancer | 19259404 | CNVD |
Malignant peripheral nerve sheath tumor | 18522746 | CNVD |
Bladder cancer | 21909424 | CNVD |
Pancreatic ductal adenocarcinoma | 19077451 | CNVD |
Cognitive impairment | 21505072 | CNVD |
Breast cancer | 17142309 | CNVD |
Non-syndromic sensorineural hearing loss | 17122850 | CNVD |
No. | Chromosome Location | Chromatin state | Cell line | Tissue |
---|---|---|---|---|
1 | chr8:6785800-6798800 | Enhancers | Primary neutrophils fromperipheralblood | blood |
2 | chr8:6789200-6791800 | Weak transcription | Fetal Thymus | thymus |
3 | chr8:6791400-6793000 | Flanking Active TSS | Dnd41 | blood |
4 | chr8:6791600-6792800 | Enhancers | Thymus | Thymus |
5 | chr8:6791800-6792000 | Bivalent Enhancer | Primary monocytes fromperipheralblood | blood |
6 | chr8:6791800-6793200 | Enhancers | Fetal Thymus | thymus |
7 | chr8:6792000-6792200 | Bivalent Enhancer | Monocytes-CD14+_RO01746 | blood |
8 | chr8:6792200-6792800 | Bivalent Enhancer | Primary hematopoietic stem cells | blood |
9 | chr8:6792200-6792800 | Bivalent Enhancer | Primary hematopoietic stem cells G-CSF-mobilized Male | -- |
10 | chr8:6792400-6793800 | Enhancers | Fetal Brain Male | brain |
11 | chr8:6793000-6798000 | Enhancers | Dnd41 | blood |
12 | chr8:6793200-6793600 | Weak transcription | Fetal Thymus | thymus |
13 | chr8:6793600-6793800 | Enhancers | Fetal Thymus | thymus |
14 | chr8:6793800-6800200 | Weak transcription | Fetal Thymus | thymus |
15 | chr8:6794400-6794600 | Enhancers | iPS DF 19.11 Cell Line | embryonic stem cell |